Royalty Pharma (RPRX) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $62.00 from $58.00 | Aug 7, 2026 |
| TD Cowen | Maintained | Buy | $65.00 from $50.00 | Jul 13, 2026 |
| JP Morgan | Maintained | Overweight | $58.00 from $50.00 | May 7, 2026 |
| Citigroup | Maintained | Buy | $66.00 from $50.00 | May 7, 2026 |
| UBS | Maintained | Buy | $57.00 from $51.00 | Apr 21, 2026 |
| Morgan Stanley | Maintained | Overweight | $63.00 from $61.00 | Apr 10, 2026 |
| Citigroup | Maintained | Buy | $50.00 from $48.00 | Jan 27, 2026 |
| TD Cowen | Maintained | Buy | $45.00 from $42.00 | Dec 11, 2025 |
| Morgan Stanley | Maintained | Overweight | $54.00 from $55.00 | Oct 10, 2025 |
| Goldman Sachs | Initiated Coverage | Buy | $42.00 | Sep 30, 2025 |
| Citigroup | Maintained | Buy | $42.00 from $40.00 | Jul 22, 2025 |
| Morgan Stanley | Maintained | Overweight | $54.00 from $51.00 | Jul 10, 2025 |
| Citigroup | Maintained | Buy | $40.00 from $60.00 | Oct 25, 2024 |
| Goldman Sachs | Maintained | Buy | $51.00 from $50.00 | Aug 14, 2024 |
| Morgan Stanley | Maintained | Overweight | $51.00 from $48.00 | Jul 11, 2024 |
| UBS | Downgraded | Buy → Neutral | $28.00 | Jun 3, 2024 |
| B of A Securities | Maintained | Buy | $38.00 from $40.00 | Apr 12, 2024 |
| Goldman Sachs | Maintained | Buy | $50.00 from $56.00 | Feb 20, 2024 |
| JP Morgan | Maintained | Overweight | $42.00 from $45.00 | Feb 20, 2024 |
| Morgan Stanley | Maintained | Overweight | $57.00 from $54.00 | Nov 9, 2023 |
Frequently asked questions
Is RPRX a buy, sell, or hold?
Analysts covering Royalty Pharma currently average a Buy rating: 8 buy, 1 hold and 1 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on RPRX?
On Aug 7, 2026, JP Morgan maintained Royalty Pharma at Overweight with a price target of $62.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.